Key result
Cardiovascular polypharmacy was common post-incident CVD and associated with factors including female sex (OR 0.74), current smoking (OR 1.29), obesity (OR 1.38), and comorbidities (OR 1.25).
Why the study?
The study was conducted to investigate initial cardiovascular prescription patterns after a first cardiovascular event and to identify factors associated with cardiovascular polypharmacy.
What are the initial cardiovascular prescription patterns and factors associated with cardiovascular polypharmacy in patients after their first cardiovascular event?
Cross-Sectional (n=121,600)
Yes
What are the initial cardiovascular prescription patterns and factors associated with cardiovascular polypharmacy in patients after their first cardiovascular event?
Odds Ratio: 0.74 (95% CI 0.72–0.76)
Multiple cardiovascular drug treatment is common following an incident cardiovascular event in the UK, with high-risk factors strongly associated with polypharmacy.
Polypharmacy common post-first CVD with identifiable predictors; hypothesis-generating for longitudinal outcomes and deprescribing trials.
AIMS: The aim of this study was to investigate the initial cardiovascular prescription patterns in patients after their first cardiovascular events, and to identify factors associated with cardiovascular polypharmacy. METHODS: This was a cross-sectional study including patients aged ≥ 45 years with the first record of coronary heart disease (CHD) or stroke between 2007 and 2016 using The Health Improvement Network database. This study investigated the patterns of cardiovascular drugs prescribed during the first 90 days after the first cardiovascular events. Logistic regression was used to examine the association between patients' baseline characteristics and cardiovascular polypharmacy (≥5 cardiovascular drugs). RESULTS: A total of 121,600 (59,843 CHD and 61,757 stroke) patients were included in the study. The mean age was 69.5 ± 11.9 years. The proportion of patients who were prescribed 0-1, 2-3, 4-5 drugs and ≥6 drugs were 11.0%, 29.8%, 38.6% and 20.5%, respectively. Factors associated with cardiovascular polypharmacy were sex (female: OR 0.74, 95% CI 0.72-0.76 vs male), age (75-84 years old: OR 0.50, 0.47-0.53 vs 45-54 years old), smoking status (current smoking: OR 1.29, 1.15-1.24 vs never), body mass index (obesity: OR 1.38, 1.34-1.43 vs normal), deprivation status (most deprived: OR 1.09, 1.04-1.14 vs least deprived) and Charlson comorbidity index (index ≥5: OR 1.25, 1.16-1.35 vs index 0). CONCLUSION: Multiple cardiovascular drugs treatment was common in patients with CVD in the UK. High-risk factors of CVD were also associated with cardiovascular polypharmacy. Further studies are warranted to assess the impact of cardiovascular polypharmacy and its interaction on CVD recurrence and mortality.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2020) conducted a cross-sectional in Incident cardiovascular events (coronary heart disease or stroke) (n=121,600). High-risk baseline characteristics (e.g., female sex, smoking, obesity, comorbidities) vs. Reference baseline characteristics (e.g., male sex, never smoking, normal BMI) was evaluated on Cardiovascular polypharmacy (≥5 cardiovascular drugs) (OR 0.74, 95% CI 0.72-0.76). Cardiovascular polypharmacy was common post-incident CVD and associated with factors including female sex (OR 0.74), current smoking (OR 1.29), obesity (OR 1.38), and comorbidities (OR 1.25).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: